Needham Reiterates Buy on Sarepta Therapeutics, Maintains $205 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum has reiterated a Buy rating on Sarepta Therapeutics (NASDAQ:SRPT) and maintained a price target of $205.
October 14, 2024 | 10:46 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Gil Blum has reiterated a Buy rating on Sarepta Therapeutics and maintained a price target of $205, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $205 price target by Needham suggests a positive outlook for Sarepta Therapeutics. This could lead to increased investor confidence and potentially a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100